avelumab,paclitaxel,pelareorep
pfizer,merck,oncolytics biotech
['bracelet-1', 'paclitaxel', 'avelumab']
at #asco23 results from bracelet-1 study, testing the oncolytic reovirus pelareorep + paclitaxel +/- avelumab in hr+/her2-neg bc oor at 16 wks 31%
6-month pfs 86% addition of avelumab toxicity, not in efficacy 
MD, Medical Oncologist🇮🇹•Research Fellow at @JulesBordet Institute in Brussels🇧🇪 Great interest in #BreastCancer and #ImmunoOncology